サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1785724

抗レトロウイルス薬の世界市場

Anti-Retroviral Drugs

出版日
ページ情報
英文 280 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
抗レトロウイルス薬の世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 280 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗レトロウイルス薬の世界市場は2030年までに348億米ドルに達する見込み

2024年に294億米ドルと推定された抗レトロウイルス薬の世界市場は、2024～2030年の分析期間においてCAGR 2.9%で成長し、2030年には348億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるマルチクラス併用薬は、CAGR 2.8%を記録し、分析期間終了時には113億米ドルに達すると予想されます。ヌクレオシド逆転写酵素阻害剤セグメントの成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は80億米ドル、中国はCAGR 5.4％で成長すると予測

米国の抗レトロウイルス薬市場は、2024年に80億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに68億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.2%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の抗レトロウイルス薬市場- 主要動向と促進要因まとめ

なぜ抗レトロウイルス薬の需要が増加しているのか？

HIV/AIDSの世界の負担は、公衆衛生上の大きな課題であり続けており、2023年時点でHIVとともに生きる人の数は3,900万人と推定されています。HIV/AIDSの蔓延を抑えるために大きな前進が見られる一方で、新規感染者の増加、薬剤耐性の増加、生涯にわたる治療継続の必要性により、抗レトロウイルス薬（ARVs）の需要が高まっています。曝露前予防薬（Pre-Exposure Prophylaxis、PrEP）と曝露後予防薬（Post-Exposure Prophylaxis、PEP）の導入により、ARVの用途は治療以外にも拡大し、高リスク集団における予防の取り組みが強化されています。さらに、長時間作用型の注射治療薬や副作用の少ない次世代ARVは、患者のアドヒアランスとQOLを向上させ、治療の展望を再構築しています。

科学的イノベーションはARV療法をどのように変革しているか？

薬理ゲノミクス、ナノメディシン、CRISPRベースの遺伝子編集における著しい進歩は、より効果的で個別化されたHIV治療への道を開いています。長時間作用型の注射薬（例えば、カボテグラビルやリルピビリン）の開発により、毎日の経口薬への依存が減り、患者の利便性が向上しました。さらに、広範中和抗体（bNAbs）はHIV治療における有望なアプローチとして台頭してきており、複数のウイルス株を高い有効性で標的としています。インテグラーゼ阻害薬（INSTI）、非ヌクレオシド系逆転写酵素阻害薬（NNRTI）、プロテアーゼ阻害薬（PI）を統合した併用療法は、ウイルス抑制率を向上させながら耐性リスクを最小化するゴールドスタンダードになりつつあります。さらに、AIを活用した創薬プラットフォームにより、効力が向上し、副作用の少ない次世代ARVの開発が加速しています。

市場の課題と治療アクセスへの障壁とは？

医療の進歩にもかかわらず、いくつかの課題が世界の抗レトロウイルス薬市場に影響を与え続けています。薬剤耐性は依然として重大な問題であり、一部の患者は第一選択薬のARVレジメンに対して耐性を獲得しているため、第二選択薬や第三選択薬の開発が必要となっています。さらに、特に医療インフラが不十分なことが多い中低所得国（LMICs）では、治療へのアクセスや経済的な負担が依然として大きな問題となっています。HIV/AIDSにまつわるスティグマ（烙印）は、早期診断と治療開始の妨げとなっており、より強力な公衆衛生キャンペーンとコミュニティベースの介入プログラムが必要です。さらに、規制上のハードル、厳しい承認プロセス、サプライチェーンの混乱は、発展途上地域における革新的なARV製剤のタイムリーな入手に影響を与え続けています。

抗レトロウイルス薬市場の成長の原動力は？

抗レトロウイルス薬市場の成長は、HIV/AIDSの世界的有病率の上昇、HIV治療プログラムに対する政府資金の増加、有効性が強化され副作用が軽減された新規ARV製剤の発売など、いくつかの要因によって牽引されています。世界エイズ・結核・マラリア対策基金（Global Fund）、ペップファー（PEPFAR）、ユナイテッド・エイズ（UNAIDS）などが主導する官民パートナーシップの拡大により、十分な治療を受けていない地域における安価なARVへのアクセスが大幅に改善されました。さらに、長時間作用型治療や次世代HIV治療へのシフトは、患者がより便利で服薬アドヒアランスに配慮した選択肢を求めているため、市場の成長を後押ししています。新興市場ではジェネリックARVの採用が増加しており、また徐放性ドラッグデリバリー・システムの技術的進歩も、入手しやすさと手頃な価格をさらに後押ししています。さらに、HIVの機能的治療薬や治療用ワクチンの開発が進んでいることも、市場の将来的な軌道を形成し続け、今後10年間の大幅な拡大に向けた位置づけとなっています。

セグメント

薬剤クラス別（多剤併用療法薬、ヌクレオシド系逆転写酵素阻害薬（NRTI）、非ヌクレオシド系逆転写酵素阻害薬（NNRTI）、プロテアーゼ阻害薬、インテグラーゼ阻害薬、その他の薬剤クラス）、薬剤タイプ別（ブランド薬、ジェネリック薬）、

調査対象企業の例

  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc
  • GSK Plc
  • Jaguar Health
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29190

Global Anti-Retroviral Drugs Market to Reach US$34.8 Billion by 2030

The global market for Anti-Retroviral Drugs estimated at US$29.4 Billion in the year 2024, is expected to reach US$34.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Multi-Class Combination Drugs, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$11.3 Billion by the end of the analysis period. Growth in the Nucleoside Reverse Transcriptase Inhibitors segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.0 Billion While China is Forecast to Grow at 5.4% CAGR

The Anti-Retroviral Drugs market in the U.S. is estimated at US$8.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.8 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Anti-Retroviral Drugs Market - Key Trends & Drivers Summarized

Why Is the Demand for Anti-Retroviral Drugs Increasing?

The global burden of HIV/AIDS continues to be a major public health challenge, with an estimated 39 million people living with HIV as of 2023. While significant strides have been made in controlling the epidemic, the increasing number of new infections, rising drug resistance, and the need for lifelong treatment adherence have fueled demand for anti-retroviral drugs (ARVs). The introduction of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) has expanded ARV applications beyond treatment, enhancing prevention efforts in high-risk populations. Additionally, long-acting injectable therapies and next-generation ARVs with fewer side effects are reshaping the treatment landscape, improving patient adherence and quality of life.

How Are Scientific Innovations Transforming ARV Therapies?

Significant advancements in pharmacogenomics, nanomedicine, and CRISPR-based gene editing are paving the way for more effective and personalized HIV treatments. The development of long-acting injectables (e.g., Cabotegravir and Rilpivirine) has reduced the dependency on daily oral medications, enhancing convenience for patients. Moreover, broadly neutralizing antibodies (bNAbs) are emerging as a promising approach in HIV therapy, targeting multiple strains of the virus with high efficacy. Combination therapies integrating integrase inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) are becoming the gold standard, minimizing resistance risks while improving viral suppression rates. Additionally, AI-driven drug discovery platforms are expediting the development of next-generation ARVs with improved potency and fewer side effects.

What Are the Market Challenges and Barriers to Treatment Access?

Despite medical advancements, several challenges continue to impact the global anti-retroviral drugs market. Drug resistance remains a critical issue, with some patients developing resistance to first-line ARV regimens, necessitating the development of second- and third-line therapies. Additionally, treatment accessibility and affordability remain major concerns, particularly in low- and middle-income countries (LMICs), where healthcare infrastructure is often inadequate. The stigma surrounding HIV/AIDS further hinders early diagnosis and treatment initiation, necessitating stronger public health campaigns and community-based intervention programs. Furthermore, regulatory hurdles, stringent approval processes, and supply chain disruptions continue to affect the timely availability of innovative ARV formulations in developing regions.

What’s Driving the Growth of the Anti-Retroviral Drugs Market?

The growth in the anti-retroviral drugs market is driven by several factors, including the rising global prevalence of HIV/AIDS, increasing government funding for HIV treatment programs, and the launch of novel ARV formulations with enhanced efficacy and reduced side effects. The expansion of public-private partnerships, such as those spearheaded by the Global Fund, PEPFAR, and UNAIDS, has significantly improved access to affordable ARVs in underserved regions. Moreover, the shift toward long-acting therapies and next-generation HIV treatments is propelling market growth, as patients seek more convenient and adherence-friendly options. The increasing adoption of generic ARVs in emerging markets, along with technological advancements in sustained-release drug delivery systems, is further driving accessibility and affordability. Additionally, the ongoing development of HIV functional cures and therapeutic vaccines continues to shape the future trajectory of the market, positioning it for significant expansion in the coming decade.

SCOPE OF STUDY:

The report analyzes the Anti-Retroviral Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors, Integrase Inhibitors, Other Drug Classes); Drug Type (Branded Drugs, Generic Drugs);

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc
  • GSK Plc
  • Jaguar Health
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Anti-Retroviral Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global HIV Prevalence Fueling Demand for Anti-Retroviral Therapies
    • Growing Innovations in Long-Acting Anti-Retroviral Drug Formulations
    • Increasing Adoption of Fixed-Dose Combination Therapies for HIV Treatment
    • Expanding Role of AI & Big Data in Personalized Anti-Retroviral Drug Development
    • Surging Investments in Pediatric & Geriatric HIV Treatment Solutions
    • Technological Advancements in Nanomedicine for Improved Drug Delivery
    • Growing Demand for Affordable & Accessible Anti-Retroviral Therapies
    • Increasing Research in HIV Cure Strategies & Functional Remission Approaches
    • Expanding Availability of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention
    • Rising Integration of Digital Health & Telemedicine in HIV Treatment Management
    • Increasing Public-Private Partnerships for Advancing Anti-Retroviral Research
    • Emerging Role of mRNA & Gene Therapy in Next-Generation HIV Treatments
    • Expansion of Government Initiatives & Funding for HIV Treatment Access
    • Growing Adoption of Community-Based Distribution Models for Anti-Retrovirals
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anti-Retroviral Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anti-Retroviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Multi-Class Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Multi-Class Combination Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Multi-Class Combination Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Non-Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Non-Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Non-Nucleoside Reverse Transcriptase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Protease Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Branded Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Branded Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • JAPAN
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • CHINA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • EUROPE
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Anti-Retroviral Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • FRANCE
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • GERMANY
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Anti-Retroviral Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • INDIA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Anti-Retroviral Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Anti-Retroviral Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Anti-Retroviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030
  • AFRICA
    • Anti-Retroviral Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Anti-Retroviral Drugs by Drug Class - Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Anti-Retroviral Drugs by Drug Class - Percentage Breakdown of Value Sales for Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Anti-Retroviral Drugs by Drug Type - Branded Drugs and Generic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Anti-Retroviral Drugs by Drug Type - Percentage Breakdown of Value Sales for Branded Drugs and Generic Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION